Prostate Cancer | Specialty

Advancements in Prostate Cancer Screening Give Urologists More Options

December 17th 2015

Philip J. Buffington, MD, discussed new screening methods and hormonal therapies being utilized for patients with metastatic prostate cancer.

Dr. O'Sullivan on Safety Profile of Radium-223

December 16th 2015

Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queen’s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.

Advanced Prostate Cancer Clinics Make Inroads in Practices

December 15th 2015

Gary Kirsh, MD, president of The Urology Group and LUGPA, Kirsh provides insight on treating prostate cancer within the context of urology, as well as the benefits of a multidisciplinary approach.

Urologists Adapt Treatment Paradigm to Incorporate Novel Agents in mCRPC

December 15th 2015

Raoul S. Concepcion, MD, FACS, discussed novel therapies for treating mCRPC and deciding which patients are appropriate candidates.

Experts Urge Early Therapy and Less Delay in Treating Advanced Prostate Cancer

December 15th 2015

Amid an expansion of therapeutic options for men with advanced prostate cancer, evidence is building that introducing recently developed agents and regimens earlier in the treatment timeline can benefit patients in several disease settings.

Prostate Cancer Guidelines Lack Molecular Test Recommendations

December 15th 2015

When compared with the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, the corresponding prostate cancer guidelines fall short in one distinct characteristic—the lack of a molecular test in tissue-based platforms at this point in time.

Multiple Trials Explore Radium-223 Combinations for mCRPC

December 15th 2015

Clinical trials are now assessing how to best use radium-223 (Xofigo) in combination with androgen inhibitors, following the rapid approval of several agents for men with castration-resistant prostate cancer.

Men With High-Risk Prostate Cancer Undergoing More Prostatectomies

December 2nd 2015

Recent trends suggest a shift away from radiation therapy and more toward radical prostatectomy for patients with high-risk prostate cancer.

Cabazitaxel Use in Metastatic Prostate Cancer

November 30th 2015

Impact of Volume of Disease in Prostate Cancer

November 30th 2015

Hormone-Sensitive Metastatic Prostate Cancer

November 30th 2015

Costs Associated with Prostate Cancer Treatment

November 30th 2015

The Role of Sipuleucel-T in Advanced Prostate Cancer

November 30th 2015

Monitoring During Radium-223 Treatment in Prostate Cancer

November 30th 2015

Managing Pain in Patients with Prostate Cancer

November 30th 2015

Benefits of Radiopharmaceuticals in mCRPC

November 30th 2015

Early Treatment Approaches in Prostate Cancer

November 30th 2015

Managing mCRPC Patients on Abiraterone

November 30th 2015

AR Targeted Therapy for Nonmetastatic CRPC

November 30th 2015

Importance of Molecular Changes in Prostate Cancer

November 30th 2015